Xinsu Biotech Secures RMB 100 Million Pre-A Funding to Accelerate High-Throughput DNA Synthesis Chip Development and Market Expansion

VBInsight learned at the first opportunity that, recently,Xinsu Technology Announces Completion of Hundred-Million-Yuan Pre-A and Pre-A+ Funding Rounds, with participation from Green Dynamics Capital, Fosun Health Capital under the Fosun Group, Ali Health, and existing shareholders FreeS Fund, Qiming Venture Partners, Jiacheng Capital, and Xinhang Capital. The funds raised in this round will be primarily used for product R&D, service operations, and capacity expansion. Xinsu Medical Technology is about to launch a new round of financing.

Xinsu Technology was founded in 2021 with the vision of developing molecular chips using semiconductor technologies such as integrated circuits, thereby driving the semiconductization of biotechnology. The company’s initial application focus is high-throughput DNA synthesis, aiming to achieve an exponential reduction in DNA synthesis costs through CMOS chip-based gene synthesis technology. Currently, Xinsu Technology has successfully taped out China’s first independently developed short-chain CMOS chip. In addition to chip-based synthesis, Xinsu Technology has also strategically laid out enzymatic biological methods. Enzymatic and chip-based approaches for DNA synthesis are two complementary pathways; the company is currently developing new controllable strategies to enhance enzyme efficiency and adapt automated methods for enzymatic synthesis.

Huang Kuan, Managing Director of Investments at Green Capital“The convergence of two strategic high grounds—semiconductors and biotechnology—has driven the underlying technologies such as gene synthesis and sequencing to evolve at a pace surpassing ‘Moore’s Law,’ serving as the core driver for the rapid development of biomanufacturing in the 21st century. Xinsu Technology has integrated top-tier global teams from the fields of semiconductors, microfluidics, and molecular biology, demonstrating exceptional execution capabilities in commercialization and service delivery, and has successfully achieved tape-out of China’s first independently developed gene synthesis chip. Furthermore, through ultra-high-throughput biochips, Xinsu has enabled improvements of two to three orders of magnitude in reagent usage efficiency, waste emissions, and recyclability in biological R&D, making it a significant driving force for the green and sustainable development of biomanufacturing. We look forward to Xinsu continuing to overcome challenges in the strategic competition for underlying technologies such as long-chain DNA synthesis and gene storage, and becoming a global leader.”

Qin Zheng, Executive Director of the Investment Department at Ali Health“It stated: ‘In the era of digital biology, gene and cell therapy, and synthetic biology, the understanding and manipulation of biological macromolecules such as DNA and RNA constitute a critical foundational capability. As an upstream sector of the life sciences industry, DNA synthesis serves fundamental scientific research, cell factories, biopharmaceuticals, DNA data storage, and other fields, playing a significant role in the life sciences domain. Building on its previous “biochip” foundations, Xinsu Technology is developing and realizing its vision of “molecular chips,” continuously advancing the semiconductorization of biotechnology, which holds important strategic value for China’s advanced biotechnology sector. We highly recognize the team led by Dr. Zhao Xin and look forward to Xinsu Technology’s products entering the industrialization phase soon, bringing breakthrough benefits to the life sciences industry. Alibaba is pleased to participate in this financing round and will work together with the team to provide long-term empowerment and benefit society.’”

Qiming Venture Partners Partner Chen Kan“High-throughput DNA synthesis serves as a critical foundation for the advancement of modern biotechnology, yet its research and development are fraught with challenges. As one of the pioneers in this field, Xinsu Technology is a rare enterprise possessing multidisciplinary expertise spanning integrated circuits, MEMS, organic chemistry, and biochemistry, positioning it well to achieve breakthroughs in next-generation technologies. Since the previous financing round, the company has reached several major milestones, fully demonstrating the team’s strong execution capabilities and drive. Consequently, Qiming Venture Partners has continued to increase its investment. We are pleased to continue supporting the company’s growth, remain firmly confident in its development potential in the field of high-throughput DNA synthesis, and look forward to its ongoing revolutionary innovations that will build a world-leading technology platform and drive the development of the global biomedical industry.”

Ma Rui, Partner at FreeS Fund“Congratulations to Dr. Zhao Xin and his team for securing significant financing against the odds during an economic downturn. The cross-disciplinary integration of semiconductor technology and biotechnology is an effective pathway to disruptive innovation. In the two short years since FreeS Fund’s angel investment in Xinsu, the company has accelerated its growth, achieving breakthroughs in high-throughput synthesis of short DNA strands and long-strand assembly chips, while initially realizing commercial deployment. We look forward to Xinsu making new strides in broad sectors such as synthetic biology, agriculture, sequencing, and pharmaceuticals.”

Fosun Health CapitalJin Bi, Executive General Manager of Capital InvestmentHe stated, “As an industrial investor, we are highly optimistic about the future development and application potential of high-throughput DNA synthesis technology platforms. The Xinsu team has demonstrated efficient execution and outstanding professional capabilities, successfully achieving breakthroughs in underlying technologies and completing the prototype development of a semiconductor-based DNA synthesis platform, which has passed our relevant tests. Fosun Health Capital Suzhou Fund is delighted to participate in supporting the company’s growth, and we believe that through the diligent efforts of the founding team and the company, Xinsu Medical will further enhance its platform’s technical capabilities and expand its application scenarios, establishing itself as a leading enterprise in China’s high-throughput DNA synthesis sector.”

Zhao Xin, Founder and CEO of Xinsu Medical Technology“He extends his sincere gratitude to both new and existing shareholders for their strong support of Xinsu Technology, and thanks industrial partners for their recognition of Xinsu Technology’s technological and commercialization capabilities. Semiconductor chips represent a foundational technology characterized by the smallest controllable scale, the largest integration density, and the most diverse functionalities. Following this round of financing, Xinsu Technology will further deepen its focus on ‘semiconductors + molecular chips’ across five key dimensions: technology, platform, manufacturing, team, and pipeline. By leveraging molecular chips as critical infrastructure, the company will continue to drive innovation and breakthroughs in foundational technologies, empowering application fields such as synthetic biology, biopharmaceuticals, diagnostics and sequencing, agriculture, and data storage, thereby providing more comprehensive, efficient, and cost-effective solutions for industry development.”

Xinsu Technology’s vision is to leverage semiconductor technology to build the infrastructure for the era of molecular biology, dedicating itself to the high-throughput synthesis and detection of DNA, RNA, proteins, and peptides. The company aims to reduce the synthesis costs of biological macromolecules such as DNA by orders of magnitude, facilitate the AI-driven paradigm shift in biological R&D, and empower key frontier industries including synthetic biology, biopharmaceuticals, and DNA data storage. The company regards “independent and controllable core technology R&D,” “matrix design of innovation units,” and “innovative exploration in frontier fields and interdisciplinary areas” as its core competencies driving corporate development.

Green Dynamics Capital is a private equity fund in China dedicated to green impact investing. Established in 2016, it manages assets exceeding RMB 15 billion. The firm primarily focuses on equity investments in high-growth companies driven by green and digital technologies, spanning sectors such as clean energy, new materials, advanced green manufacturing, green low-carbon transportation, and energy conservation and environmental protection. Green Dynamics Capital is among the earliest investment institutions in China to implement systematic quantitative assessments and authoritative certifications of green impact. Adhering to its mission of “Investing · Energizing China · Influencing Asia,” the firm empowers technological innovation through capital, injects new green momentum into corporate development, and pursues a win-win outcome of financial returns and environmental benefits. Owing to its strong investment performance and market influence, Green Dynamics Capital has been repeatedly honored by authoritative organizations as a “Most Green Impactful” private equity fund and one of “China’s Best ESG Institutions.”

Ali Health is the flagship platform of Alibaba Group that integrates online and offline resources in the pharmaceutical and healthcare industries to provide one-stop medical solutions. Centered on user needs, Ali Health leverages its existing strengths in pharmaceutical e-commerce while exploring innovative business models for internet-based healthcare. Built upon leading digital technologies and digital operational capabilities, with “cloud infrastructure” as the foundation, “cloud pharmacy” as the core, and “cloud hospital” as the engine, Ali Health delivers inclusive, convenient, efficient, and safe healthcare services to hundreds of millions of families. The Zijin Hongyun Fund, co-managed (Co-GP) by Ali Health and Huatai Zijin, is a specialized fund focused on the greater health industry, primarily investing in sectors such as biopharmaceuticals, medical devices, in vitro diagnostics, and consumer healthcare.

Qiming Venture Partners, established in 2006, has successively set up offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston, and the San Francisco Bay Area. Currently, Qiming Venture Partners manages 11 US dollar funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early-stage and growth-stage companies in the Technology and Consumer (T&C) and Healthcare sectors. To date, Qiming Venture Partners has invested in more than 530 high-growth innovative enterprises, among which over 200 have exited through listings on major exchanges—including the New York Stock Exchange, NASDAQ, Hong Kong Stock Exchange, Shanghai Stock Exchange, and Shenzhen Stock Exchange—as well as through mergers and acquisitions. More than 70 of these portfolio companies have become industry-recognized unicorns and super unicorns.

FreeS Fund, established in 2015, has evolved into a full-spectrum fund management firm driven by early-stage investments while actively positioning itself across growth, mid, and late stages. Focusing on three core sectors—Consumer & TMT, Hard Tech, and Biopharma—FreeS Fund has invested in over 150 innovative enterprises, spanning lifestyle, culture and entertainment, intelligent manufacturing, artificial intelligence, biotechnology and novel drug R&D, new energy, and advanced materials. Research-driven and innovation-oriented, FreeS Fund has developed a distinctive investment strategy through continuous exploration: identifying unique opportunities at the intersection of disciplines. We believe that interdisciplinary fields typically represent the most promising directions and opportunities for technological innovation, as breakthrough innovations often emerge at the crossroads of scientific disciplines.

Fosun Health Capital (Shanghai Fosun Health Equity Investment Fund Management Co., Ltd.) is a holding subsidiary established by Fosun Pharma to serve as its fund management arm. Leveraging Fosun Pharma’s advantages accumulated over more than 20 years in the biopharmaceutical industry, as well as Fosun’s experience collaborating with leading domestic and international funds and companies, Fosun Health Capital specializes in the entrusted management of funds focused on the broader healthcare sector. The firm manages multiple RMB-denominated funds dedicated to investing in the medical and healthcare space, with assets under management nearing RMB 5 billion. It primarily invests across various sub-sectors of healthcare, including biopharmaceuticals, high-end medical devices, in vitro diagnostics, life sciences, and diagnostic and therapeutic technologies, realizing capital appreciation through diverse exit strategies. By synergizing with Fosun’s global R&D capabilities and industrial layout, Fosun Health Capital provides full-lifecycle empowerment to portfolio companies, driving their growth and development.